<p dir="ltr">Multi-ancestry GWAS meta-analysis on 12 cohorts comprising a total of 56,146 AD cases and 602,280 controls of European (EUR), Asian (ASN), African (AFR), American (AMR) and admixed ancestries (AD_GWAS_12meta_FE_hg38_final.txt.gz).</p><p dir="ltr">Ancestry-stratified GWAS statistics were obtained by performing an analogous meta-analysis strategy considering cohorts stratified by continental populations: EUR, ASN, AFR (AD_GWAS_EUR_meta_FE_hg38_final.txt.gz, AD_GWAS_ASN_meta_FE_hg38_final.txt.gz, AD_GWAS_AFR_meta_FE_hg38_final.txt.gz).</p><p dir="ltr">GWAS meta-analysis statistics were obtained by fixed-effect (FE) inverse variance weighted meta-analysis of the summary statistics (beta values) from each cohort using GWAMA. Genomic locations provided for human genome build 38 and hg19 (see column headers).</p><h4><b>GWAS meta-analysis design:</b></h4><table><tr><td><p dir="ltr"><b>Meta-analysis</b></p></td><td><p dir="ltr"><b># cohorts</b></p></td><td><p dir="ltr"><b>Ancestry</b></p></td><td><p dir="ltr"><b># Cases</b></p></td><td><p dir="ltr"><b># Controls</b></p></td><td><p dir="ltr"><b># GWS loci</b></p></td><td><p dir="ltr"><b>Lambda GC (all variants)</b></p></td></tr><tr><td><p dir="ltr">Multi-ancestry</p></td><td><p>12</p></td><td><p dir="ltr">EUR, EAS, CSA, SAS, AFR, AMR</p></td><td><p>56146</p></td><td><p>602280</p></td><td><p>94</p></td><td><p>1.054968</p></td></tr><tr><td><p dir="ltr">EUR-only</p></td><td><p>4</p></td><td><p dir="ltr">EUR</p></td><td><p>42963</p></td><td><p>408472</p></td><td><p>76</p></td><td><p>1.089119</p></td></tr><tr><td><p dir="ltr">ASN-only</p></td><td><p>4</p></td><td><p dir="ltr">ASN</p></td><td><p>5014</p></td><td><p>171135</p></td><td><p>12</p></td><td><p>1.054628</p></td></tr><tr><td><p dir="ltr">AFR-only</p></td><td><p>2</p></td><td><p dir="ltr">AFR</p></td><td><p>7063</p></td><td><p>15879</p></td><td><p>0</p></td><td><p>1.016833</p></td></tr></table><h4><b>Each file contains the following column headers:</b><br><b>CHR:</b> hg38 marker chromosome<br><b>POS:</b> hg38 marker position (bp)<br><b>REF:</b> reference allele<br><b>ALT:</b> effect allele<br><b>MARKER:</b> marker in format chr:pos:ref:alt (hg38, ex. 1:10177:A:AC)<br><b>rsID:</b> dbSNP rsID<br><b>PVAL:</b> meta-analysis p-value<br><b>BETA:</b> overall beta value for meta-analysis<br><b>SE:</b> beta standard error<br><b>Z:</b> Z-score<br><b>ALT_AF:</b> alternate/effect allele frequency<br><b>n_studies:</b> number of studies with marker present<br><b>n_samples:</b> number of samples with marker present<br><b>effects:</b> summary of effect directions ('+' - positive effect of ALT allele, '-' - negative effect of ALT allele, '0' - no effect (or non-significant) effect of ALT allele, '?' - missing data)<br><b>hg19_CHR:</b> hg19 marker chromosome<br><b>hg19_POS:</b> hg19 marker position<br><b>q_statistic: </b>Cochran's heterogeneity statistic<br><b>q_p-value</b>: Cochran's heterogeneity statistic's p-value<br><b>i2:</b> Heterogeneity index I2 by Higgins et al 2003</h4><p></p>
Funding
Financial support for this research was provided by AbbVie.
I confirm there is no human personally identifiable information in the files or description shared
Yes
I confirm the files and description shared may be publicly distributed under the license selected
Yes
Competing Interest Statement
Bridget Riley-Gillis is a employee of AbbVie. AbbVie participated in the design, study conduct, interpretation of data, review, and approval of the publication. The remaining authors declare no competing interests.